Literature DB >> 8324417

Interleukin-6 inhibits bone formation in vitro.

F J Hughes1, G L Howells.   

Abstract

Interleukin-6 (IL-6) is a pluripotent cytokine which is made by osteoblasts, but its role in bone metabolism is uncertain. The aim of this study was to test the effect of IL-6 on bone formation in vitro using a nodule-forming assay. Osteoblast-enriched calvaria cells were isolated from 2-day-old Sprague-Dawley rats and cultured in the presence of 10(-8) M dexamethasone. After 2 days, calvaria cells were treated with recombinant human IL-6 for 72 h, washed and maintained for a further 18 days before fixation. IL-6 caused a dose-dependent inhibition of bone nodule formation, with a maximum reduction of 53% with 5000 U/ml IL-6. IL-6 also inhibited alkaline phosphatase activity in a dose-dependent manner (e.g. control: 114 +/- 9.2; IL-6: 68 +/- 10.6 nmol p-nitrophenol (pNP)/mg/min). IL-6 did not affect cell numbers during early cell growth up to 6 days but caused a small but significant reduction in cell number at confluence (8 days). These results demonstrate that IL-6 inhibits bone nodule formation by rat calvaria cells in vitro and suggest that IL-6 may inhibit osteoblast differentiation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8324417     DOI: 10.1016/s0169-6009(08)80117-1

Source DB:  PubMed          Journal:  Bone Miner        ISSN: 0169-6009


  22 in total

Review 1.  Inflammatory bone loss: pathogenesis and therapeutic intervention.

Authors:  Kurt Redlich; Josef S Smolen
Journal:  Nat Rev Drug Discov       Date:  2012-03-01       Impact factor: 84.694

2.  IL-6 negatively regulates osteoblast differentiation through the SHP2/MEK2 and SHP2/Akt2 pathways in vitro.

Authors:  Shoichi Kaneshiro; Kosuke Ebina; Kenrin Shi; Chikahisa Higuchi; Makoto Hirao; Michio Okamoto; Kota Koizumi; Tokimitsu Morimoto; Hideki Yoshikawa; Jun Hashimoto
Journal:  J Bone Miner Metab       Date:  2014-07       Impact factor: 2.626

3.  Inflammatory factors in the circulation of patients with active rheumatoid arthritis stimulate osteoclastogenesis via endogenous cytokine production by osteoblasts.

Authors:  J L Pathak; N Bravenboer; P Verschueren; W F Lems; F P Luyten; J Klein-Nulend; A D Bakker
Journal:  Osteoporos Int       Date:  2014-07-16       Impact factor: 4.507

Review 4.  Perspectives on osteoporosis in pediatric inflammatory bowel disease.

Authors:  Manisha Harpavat; David J Keljo
Journal:  Curr Gastroenterol Rep       Date:  2003-06

5.  Camphorquinone inhibits odontogenic differentiation of dental pulp cells and triggers release of inflammatory cytokines.

Authors:  Reuben H Kim; Drake W Williams; Susan Bae; Rachel S Lee; Ju-Eun Oh; Shebli Mehrazarin; Tony Kim; Ki-Hyuk Shin; No-Hee Park; Mo K Kang
Journal:  J Endod       Date:  2012-10-24       Impact factor: 4.171

6.  Interleukin-6 attenuates agonist-mediated calcium mobilization in murine osteoblastic cells.

Authors:  J Green; S Schotland; Z Sella; C R Kleeman
Journal:  J Clin Invest       Date:  1994-06       Impact factor: 14.808

7.  Interleukin-6 expression and gene polymorphism are associated with severity of periodontal disease in a sample of Brazilian individuals.

Authors:  P R Moreira; P M A Lima; K O B Sathler; S A W Imanishi; J E Costa; R S Gomes; K J Gollob; W O Dutra
Journal:  Clin Exp Immunol       Date:  2007-04       Impact factor: 4.330

8.  Serum from children with polyarticular juvenile idiopathic arthritis (pJIA) inhibits differentiation, mineralization and may increase apoptosis of human osteoblasts "in vitro".

Authors:  Valéria F Caparbo; Flávia Prada; Clóvis A A Silva; Paula L Regio; Rosa M R Pereira
Journal:  Clin Rheumatol       Date:  2008-08-07       Impact factor: 2.980

9.  Interleukin-11 inhibits bone formation in vitro.

Authors:  F J Hughes; G L Howells
Journal:  Calcif Tissue Int       Date:  1993-11       Impact factor: 4.333

10.  Repression of the interleukin-6 promoter by estrogen receptor is mediated by NF-kappa B and C/EBP beta.

Authors:  B Stein; M X Yang
Journal:  Mol Cell Biol       Date:  1995-09       Impact factor: 4.272

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.